These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30029640)

  • 1. Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing.
    Mogensen MB; Rossing M; Østrup O; Larsen PN; Heiberg Engel PJ; Jørgensen LN; Hogdall EV; Eriksen J; Ibsen P; Jess P; Grauslund M; Nielsen HJ; Nielsen FC; Vainer B; Osterlind K
    BMC Cancer; 2018 Jul; 18(1):752. PubMed ID: 30029640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
    Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
    Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic and prognostic heterogeneity among RAS/BRAF
    Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
    Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
    Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
    Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles.
    Vignot S; Lefebvre C; Frampton GM; Meurice G; Yelensky R; Palmer G; Capron F; Lazar V; Hannoun L; Miller VA; André F; Stephens PJ; Soria JC; Spano JP
    Eur J Cancer; 2015 May; 51(7):791-9. PubMed ID: 25797355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative genomic analysis of primary and synchronous metastatic colorectal cancers.
    Lee SY; Haq F; Kim D; Jun C; Jo HJ; Ahn SM; Lee WS
    PLoS One; 2014; 9(3):e90459. PubMed ID: 24599305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of genomic profiling of patient-matched primary colorectal and surgical resected distant metastatic (stage IV) colorectal carcinoma for drug actionability.
    Jan YH; Lu CT; Lam AK
    Hum Pathol; 2024 Jul; 149():21-28. PubMed ID: 38862093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing.
    Zou SM; Li WH; Wang WM; Li WB; Shi SS; Ying JM; Lyu N
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2149-2159. PubMed ID: 30171333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
    Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE
    Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
    Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
    Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications.
    Balschun K; Haag J; Wenke AK; von Schönfels W; Schwarz NT; Röcken C
    J Mol Diagn; 2011 Jul; 13(4):436-45. PubMed ID: 21704278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.
    Knijn N; Mekenkamp LJ; Klomp M; Vink-Börger ME; Tol J; Teerenstra S; Meijer JW; Tebar M; Riemersma S; van Krieken JH; Punt CJ; Nagtegaal ID
    Br J Cancer; 2011 Mar; 104(6):1020-6. PubMed ID: 21364579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer.
    Joung JG; Oh BY; Hong HK; Al-Khalidi H; Al-Alem F; Lee HO; Bae JS; Kim J; Cha HU; Alotaibi M; Cho YB; Hassanain M; Park WY; Lee WY
    Clin Cancer Res; 2017 Dec; 23(23):7209-7216. PubMed ID: 28939741
    [No Abstract]   [Full Text] [Related]  

  • 16. KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer.
    Kawamoto Y; Tsuchihara K; Yoshino T; Ogasawara N; Kojima M; Takahashi M; Ochiai A; Bando H; Fuse N; Tahara M; Doi T; Esumi H; Komatsu Y; Ohtsu A
    Br J Cancer; 2012 Jul; 107(2):340-4. PubMed ID: 22617127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
    Wojas-Krawczyk K; Kalinka-Warzocha E; Reszka K; Nicoś M; Szumiło J; Mańdziuk S; Szczepaniak K; Kupnicka D; Lewandowski R; Milanowski J; Krawczyk P
    Adv Clin Exp Med; 2019 Jan; 28(1):67-73. PubMed ID: 30085422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer.
    Jesinghaus M; Wolf T; Pfarr N; Muckenhuber A; Ahadova A; Warth A; Goeppert B; Sers C; Kloor M; Endris V; Stenzinger A; Weichert W
    Am J Surg Pathol; 2015 Aug; 39(8):1140-7. PubMed ID: 25786087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exome sequencing of synchronously resected primary colorectal tumours and colorectal liver metastases to inform oncosurgical management.
    Sutton PA; Jithesh PV; Jones RP; Evans JP; Vimalachandran D; Malik HZ; Park BK; Goldring CE; Palmer DH; Kitteringham NR
    Eur J Surg Oncol; 2018 Jan; 44(1):115-121. PubMed ID: 29174709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of KRAS mutation with primary tumor location and survival in patients undergoing resection of colorectal cancers and synchronous liver metastases.
    Allievi N; Goffredo P; Utria AF; Pisano M; Poiasina E; Lucianetti A; Zhou P; Hassan I
    Chin Clin Oncol; 2019 Oct; 8(5):46. PubMed ID: 31500429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.